The role of the second binding loop of the cysteine protease inhibitor, cystatin A stefin A, in stabilizing complexes with target proteases is exerted predominantly by Leu73 Alona Pavlov
Trang 1The role of the second binding loop of the cysteine protease inhibitor, cystatin A (stefin A), in stabilizing complexes with target proteases
is exerted predominantly by Leu73
Alona Pavlova, Sergio Estrada* and Ingemar Bjo¨rk
Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala Biomedical Centre, Sweden
The aim of this work was to elucidate the roles of individual
residues within the flexible second binding loop of human
cystatin A in the inhibition of cysteine proteases Four
recombinant variants of the inhibitor, each with a single
mutation, L73G, P74G, Q76G or N77G, in the most
exposed part of this loop were generated by PCR-based
site-directed mutagenesis The binding of these variants to
papain, cathepsin L, and cathepsin B was characterized by
equilibrium and kinetic methods Mutation of Leu73
decreased the affinity for papain, cathepsin L and
cathep-sin B by 300-fold, >10-fold and 4000-fold,
respect-ively Mutation of Pro74 decreased the affinity for
cathepsin B by 10-fold but minimally affected the affinity
for the other two enzymes Mutation of Gln76 and Asn77
did not alter the affinity of cystatin A for any of the proteases
studied The decreased affinities were caused exclusively by increased dissociation rate constants These results show that the second binding loop of cystatin A plays a major role in stabilizing the complexes with proteases by retarding their dissociation In contrast with cystatin B, only one amino-acid residue of the loop, Leu73, is of principal importance for this effect, Pro74 assisting to a minor extent only in the case
of cathepsin B binding The contribution of the second binding loop of cystatin A to protease binding varies with the protease, being largest, 45% of the total binding energy, for inhibition of cathepsin B
Keywords: cathepsins; cystatin; cysteine proteases; papain; second binding loop
Cystatins are effective protein inhibitors of cysteine
pro-teases of the papain superfamily (reviewed in [1–4]) Found
both intracellularly and extracellularly, they are believed to
control the activity of normal endogenous proteases, as well
as to protect organisms from the harmful activity of
exogenous cysteine proteases [1,4–11] They are generally
classified into three families according to their size and the
presence of internal disulfide bonds Cystatins of family 1,
also called stefins, are small nonglycosylated proteins 11–
12 kDa in size without disulfide bonds Family 2 cystatins
are somewhat larger, 12–14 kDa, with a structure
stabi-lized by two disulfide bonds Kininogens, representing the
third family, are glycosylated proteins of about 50–90 kDa
The single polypeptide chain of a kininogen contains three domains resembling family 2 cystatins
Cystatins competitively inhibit the activity of papain-like cysteine proteases by binding to the active site of the latter and forming a tight, reversible protein–protein complex A model of the inhibition was initially proposed from computer docking experiments based on the X-ray structures of papain and chicken cystatin, a family 2 member [12] This model was later substantiated by the X-ray structure of a complex of the family 1 cystatin, human cystatin B (stefin B), with papain [13], the only structure of a cystatin–protease complex determined so far The N-terminal segment and two hairpin loops of the cystatin together form a hydrophobic wedge-shaped edge that fits well into the active-site cleft of papain The high degree of complementarity between the interacting surfa-ces allows the complex to form without significant conformational changes of either papain or the inhibitor [12–18] Both the similar three-dimensional structures of cystatins of families 1 and 2 [12,13,19–21] and the pronounced sequence homology and similar fold of cysteine proteases of the papain family [4,11,22–24] indicate that the general aspects of the interaction model can be extended to complexes between cystatins and other members of this protease family However, certain distin-guishing features of the structures of some cysteine proteases, such as the occluding loop of cathepsin B [25], cause the mode of inhibition to deviate somewhat for these enzymes Cystatins thus inhibit cathepsin B by a two-step reaction involving displacement of the occluding loop of the protease in the second step [26,27] Moreover,
it is apparent that the role of an individual binding region
Correspondence to I Bjo¨rk, Department of Veterinary Medical
Chemistry, Swedish University of Agricultural Sciences,
Uppsala Biomedical Centre, Box 575, SE-751 23Uppsala, Sweden.
Fax: + 46 18 550762, Tel.: + 46 18 4714191,
E-mail: Ingemar.Bjork@vmk.slu.se
Abbreviations: app, subscript denoting an apparent equilibrium or rate
constant determined in the presence of an enzyme substrate; E-64,
4-[(2S,3S)-3-carboxyoxiran-2-carbonyl- L
-leucylamido]butylguani-dine; His-tag, 10 successive histidine residues fused to an expressed
protein; k ass , bimolecular association rate constant; K d , dissociation
equilibrium constant; k diss , dissociation rate constant; K i , inhibition
constant; k obs , observed pseudo-first-order rate constant.
*Present address: PET-Centre, Uppsala University, University
Hospital, SE-751 85 Uppsala, Sweden.
(Received 12 July 2002, revised 16 September 2002,
accepted 20 September 2002)
Trang 2of the inhibitor in protease binding can differ with the
target protease [28]
The contributions of the N-terminal region and the first
binding loop of family 1 and 2 cystatins, as well as of the
second binding loop of family 2 cystatins, to the inhibition
of cysteine proteases have been elucidated [29–36] Recent
work has also demonstrated the importance of two
amino-acid residues, Leu73and His75, in the second binding loop
of the family 1 inhibitor, cystatin B, for high-affinity
binding to a number of cysteine proteases [37] The sequence
of the corresponding hairpin loop in cystatin A (stefin A),
another member of family 1, is appreciably different from
that in cystatin B; in particular, His75 of cystatin B is
substituted by Gly in cystatin A [1] Moreover, the NMR
structure of cystatin A shows that the second loop of this
inhibitor is highly flexible, which might be expected to affect
the interactions with the protease [20] It is thus unclear
whether the second binding loop of cystatin A fulfils the
same function as the second binding loops of cystatin B and
family 2 cystatins and also what residues of this loop in
cystatin A may participate in the interaction
To elucidate the role of the second binding loop of human
cystatin A in the inhibition of cysteine proteases, we have
characterized the contribution of four individual amino-acid
residues within the most exposed region of this loop (from
Leu73to Asn77) to protease binding (see Fig 1A) Four
recombinant cystatin A variants with Gly replacing each of
these amino acids were prepared, and their interaction with
papain, cathepsin L, and cathepsin B was characterized by
equilibrium and kinetic methods The results clearly show
that the second binding loop of cystatin A is important for
the stability of complexes with cysteine proteases Its
quantitative role in protease binding varies with the target
enzyme, but is especially important for cathepsin B Leu73,
which is highly conserved in family 1 cystatins, makes the
predominant contribution of all residues of the loop to the
free energy of formation of the enzyme–inhibitor complex
Pro74 is of minimal importance for the interaction with
papain and cathepsin L but participates to some extent in
cathepsin B binding However, the roles of Gln76 and
Asn77 in the protease inhibition are negligible
M A T E R I A L S A N D M E T H O D S
Construction of expression vectors for cystatin A
second-loop mutants
A previously developed expression vector containing the
human cystatin A coding sequence preceded by successive
sequences for the leader peptide for the outer membrane
protein A of Escherichia coli, a His-tag, and the recognition
site for enterokinase was used in this work [38] This vector
has a kcl857 temperature-sensitive repressor gene, allowing
induction of expression by increasing the temperature, and
an ampicillin-resistance gene [18] Residues Leu73, Pro74,
Gln76, and Asn77 within the second binding loop of
cystatin A were substituted with Gly by PCR-based
site-directed mutagenesis [39] Briefly, two mutagenic primers
and two standard PCR primers, the latter being
comple-mentary to regions of the vector flanking the
cysta-tin A-coding sequence, were used for creation of each
mutant (Table 1) The desired mutation was introduced in
two steps First, two overlapping DNA fragments, bearing
Fig 1 Model of the three-dimensional structure of the complex between cystatin A and active papain (A) Overall structure of the complex in ribbon representation, with cystatin A in green and papain in blue Residues in the second binding loop of cystatin A mutated in this work are in red Papain residues involved in interactions with the cystatin A second-binding-loop residues are in black (B) Close-up view of the interactions between residues in the second binding loop of cystatin A and papain residues The colors of the residues are as in (A) Inter-molecular hydrophobic contacts within a distance of 4 A˚ are repre-sented as dashed lines The model is derived from the X-ray structure
of the human C3S-cystatin B–S-(carboxymethyl)papain complex (PDB entry 1STF) [13].
Trang 3the same mutation, were synthesized in two separate PCRs,
in each of which a mutagenic and a standard primer were
used and the cystatin A expression vector was the template
In the next step, a larger DNA fragment containing the
entire mutant cystatin A-coding sequence was obtained by a
third PCR with the standard PCR primers and with a
mixture of the products of the previous two PCRs as
template The resulting DNA fragment was cleaved with
NcoI and BamHI, and the purified cleavage product
containing the mutant cystatin A cDNA was cloned into
the original vector between the NcoI and BamHI restriction
sites, replacing the corresponding region coding for
wild-type cystatin A [38] The vector was then transformed into
E colistrain MC 1061, made competent with CaCl2[40],
and transformants were selected by growing the bacteria on
agar plates containing ampicillin Plasmids from a number
of colonies of each mutant were purified, and those with
the correct mutant cystatin A cDNA were identified by
sequencing in an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA)
Expression and purification of cystatin A mutants
Recombinant L73G, P74G, Q76G, and N77G cystatin A
variants were expressed in E coli essentially as described
previously [18] The recombinant proteins were purified
from periplasmic extracts by immobilized metal affinity
chromatography on HisBind Resin (Novagen, Madison,
WI, USA), charged with Ni2+, or Ni/nitrilotriacetate
agarose (Qiagen, Hilden, Germany), as in previous work
[38] The His-tag was cleaved off with enterokinase (EC
3.4.21.9; Biozyme Laboratories, Blaenavon, UK), and the
liberated cystatin A mutant was isolated by
rechromato-graphy on the same affinity column [38] Intact His-tagged
fusion proteins still contaminating some preparations were
removed by absorption on a TALONTM Metal Affinity
Resin (Clontech, Palo Alto, CA, USA) by a hybrid batch/
gravity flow column procedure according to a protocol from
the manufacturer
Chicken cystatin
Forms 1 and 2 of chicken cystatin were isolated from
chicken egg white [41] The two forms have the same
sequence and are functionally identical [41], although form 2
is phosphorylated at Ser80 [42] and therefore has a lower
isoelectric point
Proteases Papain (EC 3.4.22.2) was purified, stored as inactive S-(methylthio)papain and activated before use as in previ-ous work [41] The thiol group content of the activated papain, determined by reaction with 5,5¢-dithiobis(2-nitro-benzoic acid) [43], was 0.95–1.00 mol per mol of enzyme Titrations with chicken cystatin (form 1) [41] gave a cystatin
to papain stoichiometry of 0.98 ± 0.02, indicating that the enzyme was fully active in binding cystatins Cathepsin L (EC 3.4.22.15) from sheep liver was a gift from
R W Mason, Alfred I du Pont Institute, Wilmington, DE, USA Human liver cathepsin B (EC 3.4.22.1) was obtained from Calbiochem (San Diego, CA, USA)
Determination of protein concentration Most protein concentrations were calculated from
A280measurements Molar absorption coefficients of
55 900M )1Æcm)1 for papain and S-(methylthio)papain [41], 8800M )1Æcm)1for all forms of cystatin A [18], and
11 400M )1Æcm)1for chicken cystatin [41] were used The concentration of active cathepsin L was determined by titration with 4-[(2S,3S)-3-carboxyoxiran-2-carbonyl-L -leu-cylamido]butylguanidine (E-64) [44] The concentration of cathepsin B was provided by the manufacturer
Binding stoichiometries The stoichiometries of binding of the cystatin A variants to papain were determined at least in duplicate by titrations of
1 lM active papain or S-(methylthio)papain with the variants The binding to active papain was monitored
by following the decrease in activity of the enzyme with
a chromogenic substrate [38], whereas the binding to S-(methylthio)papain was monitored by following the change in tryptophan fluorescence accompanying the interaction [41] The binding stoichiometries were deter-mined by nonlinear least-squares regression analysis of the titration curves [41]
Inhibition constants Apparent inhibition constants, Ki,app, for the inhibition of cathepsins L and B by the cystatin A mutants were obtained from the equilibrium rates of hydrolysis of a fluorogenic substrate by the enzyme at different inhibitor concentrations
Table 1 Primers for construction of expression vectors for cystatin A second-loop mutants All sequences are given in the 5¢ fi 3¢ direction Codons for Gly, replacing residues to be mutated, are underlined, and base changes introducing the mutations are in bold.
Standard All Forward GCTCAGGCGACCATGGGCCATCATCATC
Reverse CTTGCATGCCCTGCAGGTCG Mutagenic L73G Forward GTATTCAAAAGTGGTCCCGGACAAAATGAGGACTTG
Reverse TCCGGGACCACTTTTGAATACTTTCAAGTGCATATATTTATT P74G Forward CAAAAGTCTTGGCGGACAAAATGAGGACTTGGTAC
Reverse CATTTTGTCCGCCAAGACTTTTGAATACTTTCAAGTGC Q76G Forward CTTCCCGGAGGAAATGAGGACTTGGTACTTACTG
Reverse CCTCATTTCCTCCGGGAAGACTTTTGAATAC N77G Forward CGGACAAGGTGAGGACTTGGTACTTACTGGATAC
Reverse CAAGTCCTCACCTTGTCCGGGAAGACTTTTG
Trang 4[28,32] Product formation was continuously monitored in a
conventional fluorimeter (F-4000; Hitachi, Tokyo, Japan)
as in previous work [28] The substrates were
carbobenz-oxy-L-phenylalanyl-L-arginine 4-methylcoumaryl-7-amide
(Peptide Institute, Osaka, Japan) for cathepsin L and
carbobenzoxy-L-arginyl-L-arginine
4-methylcoumaryl-7-amide (Peptide Institute) for cathepsin B at
concentra-tions of 5 and 10 lM, respectively The fluorescence never
exceeded that corresponding to 5% substrate hydrolysis
Inhibitor concentrations were at least 10-fold higher than
enzyme concentrations The inhibition of the enzymes by
L73G-cystatin A was analysed at cystatin concentrations
ranging from (0.1–0.5)· Ki,app to (6–10)· Ki,app
Corres-ponding measurements with P74G-cystatin A were
per-formed at inhibitor concentrations varying from
(0.5–2)· Ki,appto (10–14)· Ki,app, whereas the range was
from (3–4)· Ki,appto (10–30)· Ki,appfor Q76G-cystatin A
and N77G-cystatin A Values of Ki,app were derived by
nonlinear regression analyses of plots of the ratio between
the inhibited and uninhibited rates of substrate hydrolysis
against inhibitor concentration [32] True inhibition
con-stants, Ki, were obtained after correction for substrate
competition [32,45,46]
Association kinetics
Association rate constants, kass,for the inhibition of papain
and cathepsins L and B by the cystatin A mutants were
determined by continuously monitoring the loss of enzyme
activity in the presence of a fluorogenic substrate in either a
conventional fluorimeter (see above) or a stopped-flow
fluorimeter (SX-17MV; Applied Biophysics, Leatherhead,
UK) [28,38] The substrate for papain was 10 lM
carbo-benzoxy-L-phenylalanyl-L-arginine
4-methylcoumaryl-7-amide (Peptide Institute), and the substrates for cathepsins
L and B and their concentrations were the same as those
used to determine Ki (see above) The fluorescence was
always lower than that given by 5% substrate hydrolysis
The concentrations of the inhibitors were at least 10-fold
higher than those of the enzymes and were varied in a 10–
20-fold range The highest inhibitor concentrations in
reactions with papain and cathepsin L were 10–20 nM,
whereas reactions with cathepsin B were analyzed at
inhibitor concentrations up to 30 lMfor L73G-cystatin A
and up to 0.3 –0.5 lM for the other mutants Apparent
pseudo-first-order rate constants, kobs,app, were obtained by
nonlinear least-squares regression analysis of the progress
curves [28] Apparent association rate constants, kass,app,
were calculated from the slopes of plots of kobs,app vs
inhibitor concentration and were corrected for substrate
competition to give the true association rate constants, kass
[28,45–47]
Dissociation kinetics
Dissociation rate constants, kdiss, for the complexes of the
cystatin A mutants with papain were determined by
dis-placement experiments, essentially as detailed previously
[14,16] Papain dissociating from the complexes was trapped
by a high excess of chicken cystatin (form 2), which binds
faster and more tightly to papain than cystatin A or the
cystatin A mutants do [14,18] (see also Results) and thereby
prevents reassociation of the cystatin A variants with the
enzyme The concentration of the cystatin A mutant– papain complexes was 2.5–5.0 lM, and the molar ratio of the displacing chicken cystatin to the complexes varied between 10-fold and 50-fold The progress of the reaction was monitored for 100–150 h by following the appearance
of the newly formed complex between papain and chicken cystatin, analyzed by ion-exchange chromatography on
a MonoQTM column (Amersham Biosciences, Uppsala, Sweden) Form 2 of chicken cystatin was used because its lower isoelectric point allows the complex with papain to be well separated and thus easily quantified in this analysis
kdisswas calculated as described previously [14]
kdiss for the complex between L73G-cystatin A and cathepsin L was determined by trapping the enzyme dissociated from the complex by a high concentration of the substrate, carbobenzoxy-L-phenylalanyl-L-arginine 4-methylcoumaryl-7-amide, which binds tightly to cathep-sin L with a Kmof 1.8 lM[45] In most experiments, the complex was formed by incubating 0.04 nM cathepsin L with 0.4 nML73G-cystatin A for 90 min, which resulted in
an essentially complete reaction, with 80% of the enzyme being saturated with the inhibitor The substrate was then added to a final concentration of 100 lM with minimal dilution of the complex Alternatively, the complex was formed by incubation of 1 nM cathepsin L with 10 nM
L73G-cystatin A for 15 min, resulting in 99% of the enzyme being bound in the complex, and this mixture was then diluted 1000-fold into 100 lMsubstrate In both cases, the dissociation of the complex was monitored in a conventional fluorimeter by continuously recording the fluorescence increase due to cleavage of the substrate by the liberated cathepsin L The fluorescence never exceeded that corresponding to 5% substrate hydrolysis kdisswas deter-mined by nonlinear least-squares regression analysis of the progress curves [15]
Fluorescence emission spectroscopy Fluorescence emission spectra of free papain and wild-type
or L73G-cystatin A, as well as of complexes of papain with either of the two cystatin A variants, were recorded in an SLM 4800S spectrofluorimeter (SLM-Aminco, Urbana, IL, USA) with an excitation wavelength of 280 nm, as described previously [16,41] Papain and cystatin concen-trations were 1.0 and 1.2 lM, respectively, giving > 99% saturation of enzyme with inhibitor in analyses of the complexes All spectra were corrected for inner-filter effects and for the wavelength dependence of the instrumental response [41] and were normalized to a fluorescence intensity of 1.0 for free papain at the wavelength of the emission maximum Difference spectra between the com-plexes and the free proteins were calculated as in [41] Protein modeling
The structure of human cystatin A in complex with active papain was modeled on to the X-ray structure of the complex between human C3S-cystatin B and S-(carboxy-methyl)papain (PDB entry 1STF) [13] with the program
SWISS-PDBViewer (http://www.expasy.ch/spdbv/) The most favorable rotamers of the side chains of the 46 residues
of cystatin A which differ from those of cystatin B [1] were initially selected by the program [48], and the
Trang 5S-carboxymethyl group of the papain moiety of the
complex was removed in the same manner The model
was then corrected by the program facility Quick and Dirty
Fixing of all side chains in the complex, followed by
Exhaustive Search Fixing of the side chains within the
Leu73–Asn77 segment in the second binding loop of
cystatin A After each of these steps, the conformation of
the second binding loop in the complex was refined by
energy minimization of the Leu73–Asn77 segment and all
neighboring residues within 6 A˚ The possibility of other
residues replacing Gly75 in the final model was evaluated by
Quick and Dirty Fixing of all side chains in the complex
after each replacement
Miscellaneous procedures
For N-terminal sequencing and determination of molecular
masses, the mutants were first desalted into 0.1% (v/v)
trifluoroacetic acid by gel chromatography on Fast-Desalting
PC 3.2/10 columns (Amersham Biosciences) N-Terminal
sequences were analyzed by Edman degradation in an
Applied Biosystems 477A Protein Sequencer Molecular
masses were measured by MALDI MS in a Kratos Kompact
MALDI 4 instrument (Kratos, Manchester, UK) as in
[18] SDS/PAGE under reducing and nonreducing
condi-tions was performed with the Tricine buffer system [49]
Experimental conditions
All equilibrium and kinetic experiments were performed at
25.0 ± 0.2C The proteases were first activated by 1 mM
dithiothreitol in the reaction buffer for 10 min at 25C The
inhibition of papain was studied in 50 mM Tris/HCl,
pH 7.4, containing 100 mM NaCl, 0.1 mM EDTA and,
except in the displacement experiments, 1 mMdithiothreitol
and 0.01% (w/v) Brij 35 The interaction with cathepsin L
was analyzed in 100 mMsodium acetate, pH 5.5, containing
100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, and
0.01% (w/v) Brij 35, whereas the buffer for cathepsin B
was 50 mMMes/NaOH, pH 6.0, containing 100 mMNaCl,
0.1 mM EDTA, 1 mM dithiothreitol, and 0.1% (w/v)
poly(ethylene glycol) 6000
R E S U L T S
Preparation, homogeneity and activity of cystatin A
mutants
Four variants of cystatin A, each with a single amino-acid
residue, Leu73, Pro74, Gln76 or Asn77, substituted by Gly
were produced by recombinant DNA techniques All these
mutations are in the most exposed part of the second
protease-binding loop of the inhibitor (Fig 1A) Residue 75
was not substituted, as it is Gly in the wild-type sequence
The expression vectors were constructed by PCR-based
site-directed mutagenesis and contained the expected mutant
sequences in the case of the L73G, P74G and N77G
mutants However, all vectors for the Q76G mutant purified
from 18 individual clones had, in addition to the desired
mutation, a Tfi C substitution in the codon for Thr83
This substitution was in the region specified by the forward
mutagenic primer for this mutant and was probably due to
an erroneously synthesized primer As this additional
mutation is silent, one of the isolated vectors was neverthe-less used for expression of Q76G-cystatin A The mutants were expressed with a removable His-tag and with a signal peptide directing the proteins to the periplasmic space of
E coli, facilitating purification
All purified mutants were > 99.5% homogeneous on SDS/PAGE N-Terminal sequencing of the first five residues confirmed that the His-tag was cleaved off properly
by enterokinase for all mutants The molecular masses, determined by MS, corresponded within 4.5 Da to those calculated from the expected amino-acid sequences, con-firming the correct length of the mutants, as well as the presence of the desired mutations All mutants bound active papain and S-(methylthio)papain with stoichiometries between 0.95 and 1.0, i.e they were essentially fully active
in inhibition of cysteine proteases
Binding affinity All four cystatin A mutants bound so tightly to papain that the affinity of the binding could not be determined by equilibrium methods, because of the instability of the enzyme at the low concentrations and the long reaction times that would have been necessary Therefore, Kdfor the interaction with papain was calculated as kdiss/kass from independently measured rate constants (see below and Table 2), as was Kdfor wild-type cystatin A binding to this enzyme in previous work [18] Only the L73G mutation caused a pronounced, 300-fold, decrease in the affinity for papain, compared with that of the wild-type inhibitor (Table 2) In contrast, the P74G, Q76G, and N77G muta-tions resulted in minimal, less than twofold, changes in affinity
The high affinity of most mutants for cathepsin L also precluded an accurate determination of Kifrom equilibrium measurements Such experiments gave only upper limits of
Kifor the interaction of P74G, Q76G, and N77G cystatin A with this protease (Table 2), similar to previous analyses of
Ki for the wild-type inhibitor [35] Moreover, as kdiss for these tight interactions could not be determined (see below),
Kd could not be calculated from the rate constants No meaningful comparisons of the affinities of the three mutants for cathepsin L with that of wild-type cystatin A were therefore possible However, a reliable Ki for the inhibition of cathepsin L by L73G-cystatin A was obtained
by equilibrium measurements and was > 10-fold higher than that for wild-type cystatin A The measured Kifor this mutant agreed well with Kdcalculated from kassand kdiss (see below and Table 2)
Ki for the inhibition of cathepsin B by all cystatin A forms was sufficiently high to be well determined by equilibrium analyses The L73G mutation caused a sub-stantial, 4000-fold, increase in Kiwhich was confirmed by calculations of Kdfrom kassand kdiss(Table 2) A smaller,
10-fold, increase in Kifor cathepsin B was also observed for the P74G mutant, whereas the affinities of both Q76G and N77G cystatin A for the enzyme differed minimally, about twofold, from that of wild-type cystatin A (Table 2) Association rate constants
The kinetics of association of the cystatin A mutants with papain, cathepsin L and cathepsin B were analyzed
Trang 6by continuously monitoring the decrease in enzyme
acti-vity against a fluorogenic substrate Most reactions were
studied by conventional fluorimetry, whereas the rapid
association of L73G-cystatin A with cathepsin B required
the use of stopped-flow measurements All progress
curves were well fitted to a single-exponential function
Plots of the dependence of kobs,app, derived from these
fits, on inhibitor concentration were linear in the
concen-tration range covered for all mutants Values of kass
were determined from the slopes of these plots All four
amino-acid substitutions in the second binding loop of
cystatin A had a marginal effect on kass for the binding
to papain, cathepsin L or cathepsin B (Table 2)
Dissociation rate constants
The low dissociation rate constants of the complexes
between the cystatin A mutants and papain were measured
by displacement of the mutants from the complexes with an
excess of a tighter-binding inhibitor, chicken cystatin, in
experiments monitored by ion-exchange chromatography Only the L73G mutation altered kdiss to any appreciable extent, increasing it by 170-fold over that for wild-type cystatin A kdiss for all other mutants was essentially unaffected, with at most a twofold increase being observed for P74G-cystatin A
kdiss of the complex between L73G-cystatin A and cathepsin L was measured by displacement experiments, in which the enzyme dissociating from the complex was cap-tured by an excess of a tight-binding fluorogenic substrate The values of kdissobtained by two modifications of this procedure agreed well with each other and with that calculated from Kiand kass(Table 2) The L73G mutation resulted in a greater than sevenfold increase in kdiss, compared with the value for wild-type cystatin A This method could not be used to determine kdiss for the complexes of the P74G, Q76G, and N77G mutants with cathepsin L, because of the high stabilities of these complexes and, consequently, very long dissociation times Moreover, the limited amounts of cathepsin L available precluded
Table 2 Equilibrium and rate constants at 25 °C for the binding of cystatin A variants with substitutions in the second binding loop to papain, cathepsin L and cathepsin B Methods and experimental conditions are described in Materials and Methods Values determined in this work are given as means ± SEM with the number of experiments in parentheses Values for wild-type cystatin A, reported previously and shown for comparison, as well as calculated values are given without errors Numbers in square brackets indicate the ratio of the corresponding constant to that for wild-type cystatin A.
Enzyme
Cystatin A form
K d
( M )
k ass
( M )1 Æs)1)
k diss
(s)1) Papain Wild-type 1.8 · 10)13a 3.1 · 10 6 a 5.5 · 10)7 a
L73G 5.8 · 10)11 b (1.58 ± 0.02) · 10 6 (9) (9.1 ± 0.9) · 10)5(3)
P74G 2.8 · 10)13b (3.64 ± 0.06) · 10 6
(9) (10.2 ± 0.7) · 10)7(3)
Q76G 1.8 · 10)13b (3.07 ± 0.02) · 10 6 (8) (5.6 ± 0.5) · 10)7(3)
N77G 0.95 · 10)13b (3.58 ± 0.07) · 10 6 (9) (3.4 ± 0.3) · 10)7(3)
Cathepsin L Wild-type £ 1 · 10)11 a 5.2 · 10 6 a
£ 5 · 10)5 a
L73G (1.09 ± 0.08) · 10)10(10) (2.98 ± 0.04) · 10 6 (10) (3.4 ± 0.4) · 10)4(3)
1.1 · 10)10 b 3.2 · 10)4 c P74G £ 2.4 · 10)11(7) (4.6 ± 0.2) · 10 6 (10)
[0.9]
£ 1.1 · 10)4 c Q76G £ 1.1 · 10)11(8) (6.3± 0.2) · 10 6
(9) [1.2]
£ 6.9 · 10)5 c N77G £ 1.1 · 10)11(8) (6.3± 0.2) · 10 6 (14)
[1.2]
£ 6.9 · 10)5 c Cathepsin B Wild-type 9.1 · 10)10 a 3.9 · 10 4 a 3.5 · 10)5 a
L73G (3.6 ± 0.2) · 10)6(11) (8.5 ± 0.3) · 10 4
(8) 0.28 ± 0.05 (8)
P74G (9.7 ± 0.6) · 10)9(10) (5.5 ± 0.2) · 10 4
(11) 5.3 · 10)4 c
Q76G (1.4 ± 0.1) · 10)9(8) (3.95 ± 0.07) · 10 4 (8) 5.5 · 10)5 c
N77G (2.4 ± 0.2) · 10)9(9) (2.26 ± 0.08) · 10 4
(11) 5.4 · 10)5 c
a
From previous work [18,35].bCalculated from k ass and k diss cCalculated from K i and k ass
Trang 7determination of kdissby the method used for papain, in
which the displacement was monitored by chromatography
Therefore, only upper limits of kdissfor the binding of these
mutants to cathepsin L could be estimated, as for wild-type
cystatin A in previous work [35] (Table 2)
Values of kdissfor the complexes of the four cystatin A
mutants with cathepsin B were calculated from Kiand kass
determined in separate experiments (Table 2) In addition,
kdiss for the L73G-cystatin A–cathepsin B complex was
obtained from the analyses of the association kinetics (see
above) as the intercept on the ordinate of the plot of kobs,app
vs inhibitor concentration and was in a good agreement
with the calculated kdiss (Table 2) The L73G mutation
markedly affected the rate of dissociation of the complex
with cathepsin B, increasing kdissby 8000-fold The P74G
mutation resulted in a smaller, 15-fold, increase in kdiss,
whereas the other mutations altered kdissminimally
Fluorescence emission difference spectra
The fluorescence difference spectra between complexes of
wild-type or L73G-cystatin A with papain and the free
proteins had minima at different wavelengths, 360 and
368 nm, respectively (Fig 2) Moreover, the spectrum for
the L73G mutant had an appreciably lower amplitude than
that for wild-type cystatin A, reflecting a smaller
fluores-cence change on interaction of the mutant than of the
wild-type inhibitor with papain These fluorescence changes must
reflect different changes in the environment of one or more
Trp side chains in papain on formation of the two enzyme–
inhibitor complexes, as cystatin A does not contain Trp [1]
D I S C U S S I O N
The X-ray structure of the complex between human
C3S-cystatin B and S-(carboxymethyl)papain reveals a number
of predominantly hydrophobic but also solvent-mediated interactions between the second binding loop of the inhibitor and papain [13] In particular, Leu73 and His75
in this loop are seen to make four and seven intermolecular contacts with the enzyme, respectively, that are < 4 A˚ in length In agreement with this structural evidence, site-directed mutagenesis has shown that the two residues contribute substantial free energy to the interaction of cystatin B with cysteine proteases [37] The sequence of the second binding loop of the related family 1 cystatin, cystatin A, differs appreciably from that of cystatin B Most notably, cystatin A lacks the essential His75 and instead has a Gly in this position [1] This substitution would
be expected to lead to loss of a number of interactions with the enzyme and therefore to considerably decrease the contribution of the second binding loop of cystatin A to the inhibition of target proteases However, the flexibility of the second binding loop of cystatin A demonstrated by NMR [20] may allow other amino acids of the loop to make additional favorable contacts with the protease, thereby compensating for the absence of this residue Alternatively, this flexibility may instead destabilize the interactions of the loop with the target protease, resulting in a lower binding energy To clarify the functional role of the second binding loop of cystatin A, we have studied the contribution by the residues within the most exposed segment of this loop to the inhibition of cysteine proteases The L73G, P74G, Q76G, and N77G mutants of cystatin A were constructed by site-directed mutagenesis, and their inhibition of papain, cathepsin L and cathepsin B was characterized
Our results show that the second binding loop of cystatin A is essential for the formation of tight complexes between the inhibitor and the cysteine proteases studied However, in contrast with cystatin B, this role is exerted predominantly by only one residue, Leu73, which is highly conserved in family I cystatins The major role of Leu73in the interactions is in stabilizing the complexes once they are formed This conclusion is indicated by the L73G mutation appreciably decreasing the affinity of cystatin A for the proteases by increasing the rate constants for dissociation
of the complexes but negligibly affecting the association rate constants This contribution of Leu73to the inhibitory ability of cystatin A varies for different target proteases, being most pronounced for the inhibition of cathepsin B The Leu73side chain thus contributes about )15 and )21 kJÆmol)1 to the unitary free energy change [50,51] accompanying the formation of the complex of cystatin A with papain and cathepsin B, respectively These changes correspond to 18 and 34%, respectively, of the total unitary free energy of binding of cystatin A to the two enzymes [18] The contribution of Leu73of cystatin A to binding of papain, which has an open active-site cleft, is comparable to that of Leu73in the second binding loop of cystatin B and to that of the essential Trp106 residue in this loop of the family 2 cystatin, cystatin C [37,52] However, the contribution of Leu73of cystatin A to binding of cathepsin B, in which the occluding loop partially blocks the active site, is substantially higher than that of the corres-ponding residue of cystatin C [52]
The results further show that one additional residue in the second binding loop of cystatin A, Pro74, aids in stabilizing the complex of the inhibitor with cathepsin B by decreasing the dissociation rate constant However, this
Fig 2 Fluorescence emission difference spectra between complexes of
human wild-type cystatin A or the L73G cystatin A variant with papain
and the free proteins Solid line, Wild-type cystatin A; dotted line,
L73G-cystatin A Fluorescence emission spectra were measured as
described in Materials and methods with papain and cystatin
con-centrations of 1.0 and 1.2 l M , respectively The difference spectra were
calculated from separately measured and corrected emission spectra
that were normalized to a fluorescence intensity of 1.0 for 1 l M papain
at the wavelength of the emission maximum [41].
Trang 8residue negligibly participates in the inhibition of papain
and most likely also of cathepsin L The side chains of
Leu73and Pro74 jointly contribute 45% of the total
unitary free energy of binding of cystatin A to cathepsin B,
demonstrating a major role of the second binding loop of
cystatin A in the inhibition of this enzyme Pro74 may be
directly involved in the interaction with cathepsin B by
providing hydrophobic interactions with the protease
Alternatively, the role of Pro74 might be to maintain an
appropriate orientation of Leu73for its specific interaction
with cathepsin B In contrast with Leu73and Pro74, the
two other residues of the second binding loop of cystatin A
studied, Gln76 and Asn77, are of minimal importance for
the affinity of the inhibitor for the cysteine proteases and
therefore presumably do not interact directly with the
enzymes The remaining residue of the loop, Gly75, may
conceivably provide backbone interactions with a target
protease, but such a contribution cannot be investigated by
the approach taken in this work
The conclusions drawn above from the results of this
work are in general agreement with modeling of the
cystatin A–papain complex Although no X-ray structure of
cystatin A is available, the NMR structure of the inhibitor is
similar to the X-ray structure of human C3S-cystatin B in
complex with S-(carboxymethyl)papain [13,20,53]
More-over, human cystatins A and B are homologous, having
identical amino acids in 52 out of 98 positions [1]
Cystatin B in the complex with papain can therefore be
used as an appropriate template for modeling of the
corresponding complex between cystatin A and this
prote-ase with reasonable accuracy [48,54] The model generated
for the complex indicates that only two residues within the
second binding loop of cystatin A, Leu73and Pro74, are
involved in interactions with papain (Fig 1B) Leu73makes
six hydrophobic interactions of 3.4–4.0 A˚ with Trp177 of
papain in the model, in agreement with the demonstration
that Leu73is essential for strong inhibition of cysteine
proteases by cystatin A The involvement of Trp177 of
papain in the interaction with Leu73is supported by the
changes caused by the L73G mutation of the fluorescence
difference spectrum characterizing the cystatin A–papain
interaction These changes indicate that one or more
tryptophans of papain, probably primarily Trp177 on the
surface of the active-site cleft, are exposed to a less
hydrophobic environment in the complex with
L73G-cystatin A [55] In the model, the side chain of Pro74 of
cystatin A also makes two hydrophobic contacts of 4 A˚
with Gln142 and Leu143of papain (Fig 1B) This
obser-vation is in apparent contrast with the demonstration that
Pro74 is unimportant for papain binding and participates
only in the inhibition of cathepsin B This discrepancy with
the experimental data thus indicates that the model is
somewhat uncertain with regard to the putative interactions
involving Pro74 However, in agreement with the
experi-mental results, the model accurately predicts that neither
Gln76 nor Asn77 of the second binding loop of cystatin A
interact with papain in the complex Moreover, although
the role of Gly75 was not investigated experimentally, the
model suggests that Gly is not the only residue in this
position compatible with high-affinity interaction with
papain The phi and psi angles of Gly75 deduced from the
model are thus within the Ramachandran plot region
sterically allowed for other types of residues Most residues
other than Gly could also be modeled into this position without observably interfering sterically with the interac-tion
In conclusion, this study shows the importance of the second binding loop of cystatin A for the binding of cysteine proteases, in particular cathepsin B The role of this loop is comparable to that of the corresponding loops of cystatin B and family 2 cystatins, to stabilize the cystatin– protease complex by decreasing the dissociation rate How-ever, in contrast with the latter inhibitors, this role is exerted almost exclusively by one residue of the loop, Leu73, although Pro74 is also of some importance for cathepsin B binding
A C K N O W L E D G E M E N T S
We are grateful to Dr A˚ke Engstro¨m (Department of Medical Biochemistry and Microbiology, Uppsala University) for molecular mass determinations and amino-acid sequencing This project was supported by the Swedish Medical Research Council (Project No 4212).
R E F E R E N C E S
1 Barrett, A.J., Rawlings, N.D., Davies, M.E., Machleidt, W., Salvesen, G & Turk, V (1986) Cysteine proteinase inhibitors of the cystatin superfamily In Proteinase Inhibitors (Barrett, A.J & Salvesen, G., eds), pp 515–569 Elsevier, Amsterdam.
2 Turk, V & Bode, W (1991) The cystatins: protein inhibitors of cysteine proteinases FEBS Lett 285, 213–219.
3 Abrahamson, M (1994) Cystatins Methods Enzymol 244, 685– 700.
4 Turk, B., Turk, V & Turk, D (1997) Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors Biol Chem 378, 141–150.
5 Henskens, Y.M.C., Veerman, E.C.I & Nieuw Amerongen, A.V (1996) Cystatins in health and disease Biol Chem Hoppe-Seyler
377, 71–86.
6 Blankenvoorde, M.F., Van’t Hof, W., Walgreen-Weterings, E., van Steenbergen, T.J., Brand, H.S., Veerman, E.C & Nieuw Amerongen, A.V (1998) Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen Porphyromonas gingivalis Biol Chem 379, 1371–1375.
7 Collins, A.R & Grubb, A (1998) Cystatin D, a natural salivary cysteine protease inhibitor, inhibits coronavirus replication at its physiologic concentration Oral Microbiol Immunol 13, 59–61.
8 Kos, J & Lah, T.T (1998) Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer Oncol Rep 5, 1349–1361.
9 Das, L., Datta, N., Bandyopadhyay, S & Das, P.K (2001) Suc-cessful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response J Immunol 166, 4020–4028.
10 Ruzindana-Umunyana, A & Weber, J.M (2001) Interactions of human lacrimal and salivary cystatins with adenovirus endo-peptidase Antiviral Res 51, 203–214.
11 Turk, V., Turk, B & Turk, D (2001) Lysosomal cysteine pro-teases: facts and opportunities EMBO J 20, 4629–4633.
12 Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J & Turk, V (1988) The 2.0 A˚ X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases EMBO J 7, 2593–2599.
13 Stubbs, M.T., Laber, B., Bode, W., Huber, R., Jerala, R., Lenarcic, B & Turk, V (1990) The refined 2.4 A˚ X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction EMBO J 9, 1939–1947.
Trang 914 Bjo¨rk, I., Alriksson, E & Ylinenja¨rvi, K (1989) Kinetics of
binding of chicken cystatin to papain Biochemistry 28, 1568–1573.
15 Bjo¨rk, I & Ylinenja¨rvi, K (1990) Interaction between chicken
cystatin and the cysteine proteinases actinidin, chymopapain A,
and ficin Biochemistry 29, 1770–1776.
16 Lindahl, P., Abrahamson, M & Bjo¨rk, I (1992) Interaction of
recombinant human cystatin C with the cysteine proteinases
papain and actinidin Biochem J 281, 49–55.
17 Turk, B., Colic, A., Stoka, V & Turk, V (1994) Kinetics of
inhibition of bovine cathepsin S by bovine stefin B FEBS Lett.
339, 155–159.
18 Pol, E., Olsson, S.L., Estrada, S., Prasthofer, T.W & Bjo¨rk, I.
(1995) Characterization by spectroscopic, kinetic and equilibrium
methods of the interaction between recombinant human cystatin
A (stefin A) and cysteine proteinases Biochem J 311, 275–282.
19 Dieckmann, T., Mitschang, L., Hofmann, M., Kos, J., Turk, V.,
Auerswald, E.A., Jaenicke, R & Oschkinat, H (1993) The
structures of native phosphorylated chicken cystatin and of a
recombinant unphosphorylated variant in solution J Mol Biol.
234, 1048–1059.
20 Martin, J.R., Craven, C.J., Jerala, R., Kroon-Zitko, L., Zerovnik,
E., Turk, V & Waltho, J.P (1995) The three-dimensional solution
structure of human stefin A J Mol Biol 246, 331–343.
21 Ekiel, I., Abrahamson, M., Fulton, D.B., Lindahl, P., Storer,
A.C., Levadoux, W., Lafrance, M., Labelle, S., Pomerleau, Y.,
Groleau, D., LeSauteur, L & Gehring, K (1997) NMR structural
studies of human cystatin C dimers and monomers J Mol Biol.
271, 266–277.
22 Rawlings, N.D & Barrett, A.J (1994) Families of cysteine
pep-tidases Methods Enzymol 244, 461–486.
23 Turk, D., Guncar, G., Podobnik, M & Turk, B (1998) Revised
definition of substrate binding sites of papain-like cysteine
pro-teases Biol Chem 379, 137–147.
24 Turk, B., Turk, D & Turk, V (2000) Lysosomal cysteine proteases:
more than scavengers Biochim Biophys Acta 1477, 98–111.
25 Musil, D., Zucic, D., Turk, D., Engh, R.A., Mayr, I., Huber, R.,
Popovic, T., Turk, V., Towatari, T., Katunuma, N & Bode, W.
(1991) The refined 2.15 A˚ X-ray crystal structure of human liver
cathepsin B: the structural basis for its specificity EMBO J 10,
2321–2330.
26 Nycander, M., Estrada, S., Mort, J.S., Abrahamson, M & Bjo¨rk,
I (1998) Two-step mechanism of inhibition of cathepsin B by
cystatin C due to displacement of the proteinase occluding loop.
FEBS Lett 422, 61–64.
27 Pavlova, A., Krupa, J.C., Mort, J.S., Abrahamson, M & Bjo¨rk, I.
(2000) Cystatin inhibition of cathepsin B requires dislocation of
the proteinase occluding loop Demonstration by release of loop
anchoring through mutation of His110 FEBS Lett 487, 156–160.
28 Bjo¨rk, I., Pol, E., Raub-Segall, E., Abrahamson, M., Rowan,
A.D & Mort, J.S (1994) Differential changes in the association
and dissociation rate constants for binding of cystatins to target
proteinases occurring on N-terminal truncation of the inhibitors
indicate that the interaction mechanism varies with different
enzymes Biochem J 299, 219–225.
29 Machleidt, W., Thiele, U., Laber, B., Assfalg-Machleidt, I., Esterl,
A., Wiegand, G., Kos, J., Turk, V & Bode, W (1989) Mechanism
of inhibition of papain by chicken egg white cystatin Inhibition
constants of N-terminally truncated forms and cyanogen bromide
fragments of the inhibitor FEBS Lett 243, 234–238.
30 Machleidt, W., Thiele, U., Assfalg-Machleidt, I., Forger, D &
Auerswald, E.A (1991) Molecular mechanism of inhibition of
cysteine proteinases by their protein inhibitors: kinetic studies with
natural and recombinant variants of cystatins and stefins Biomed.
Biochim Acta 50, 613–620.
31 Abrahamson, M., Mason, R.W., Hansson, H., Buttle, D.J.,
Grubb, A & Ohlsson, K (1991) Human cystatin C Role of
the N-terminal segment in the inhibition of human cysteine
proteinases and in its inactivation by leucocyte elastase Biochem.
J 273, 621–626.
32 Lindahl, P., Nycander, M., Ylinenja¨rvi, K., Pol, E & Bjo¨rk, I (1992) Characterization by rapid-kinetic and equilibrium methods
of the interaction between N-terminally truncated forms of chicken cystatin and the cysteine proteinases papain and actinidin Biochem J 286, 165–171.
33 Hall, A., Ha˚kansson, K., Mason, R.W., Grubb, A & Abra-hamson, M (1995) Structural basis for the biological specificity of cystatin C Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases J Biol Chem 270, 5115–5121.
34 Auerswald, E.A., Na¨gler, D.K., Assfalg-Machleidt, I., Stubbs, M.T., Machleidt, W & Fritz, H (1995) Hairpin loop mutations of chicken cystatin have different effects on the inhibition of cathe-psin B, cathecathe-psin L and papain FEBS Lett 361, 179–184.
35 Estrada, S., Pavlova, A & Bjo¨rk, I (1999) The contribution of N-terminal region residues of cystatin A (stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B, and cathepsin
L Biochemistry 38, 7339–7345.
36 Pol, E & Bjo¨rk, I (2001) Role of the single cysteine residue, Cys 3,
of human and bovine cystatin B (stefin B) in the inhibition of cysteine proteinases Protein Sci 10, 1729–1738.
37 Pol, E & Bjo¨rk, I (1999) Importance of the second binding loop and the C-terminal end of cystatin B (stefin B) for inhibition of cysteine proteinases Biochemistry 38, 10519–10526.
38 Estrada, S., Nycander, M., Hill, N.J., Craven, C.J., Waltho, J.P & Bjo¨rk, I (1998) The role of Gly-4 of human cystatin A (stefin A) in the binding of target proteinases Characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L Biochemistry
37, 7551–7560.
39 Higuchi, R., Krummel, B & Saiki, R.K (1988) A general method
of in vitro preparation and specific mutagenesis of DNA frag-ments: study of protein and DNA interactions Nucleic Acids Res.
16, 7351–7367.
40 Cohen, S.N., Chang, A.C.Y & Hsu, L (1972) Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R.-factor DNA Proc Natl Acad Sci USA 69, 2110–2114.
41 Lindahl, P., Alriksson, E., Jo¨rnvall, H & Bjo¨rk, I (1988) Inter-action of the cysteine proteinase inhibitor chicken cystatin with papain Biochemistry 27, 5074–5082.
42 Laber, B., Krieglstein, K., Henschen, A., Kos, J., Turk, V., Huber,
R & Bode, W (1989) The cysteine proteinase inhibitor chicken cystatin is a phosphoprotein FEBS Lett 248, 162–168.
43 Ellman, G.L (1959) Tissue sulfhydryl groups Arch Biochem Biophys 82, 70–77.
44 Barrett, A.J & Kirschke, H (1981) Cathepsin B, cathepsin H, and cathepsin L Methods Enzymol 80, 535–561.
45 Mason, R.W (1986) Species variants of cathepsin L and their immunological identification Biochem J 240, 285–288.
46 Dalet-Fumeron, V., Guinec, N & Pagano, M (1991) High-performance liquid chromatographic method for the simulta-neous purification of cathepsins B, H and L from human liver.
J Chromatogr 568, 55–68.
47 Hall, A., Abrahamson, M., Grubb, A., Trojnar, J., Kania, P., Kasprzykowska, R & Kasprzykowski, F (1992) Cystatin C based peptidyl diazomethanes as cysteine proteinase inhibitors: influence
of the peptidyl chain length J Enzyme Inhibition 6, 113–123.
48 Guex, N & Peitsch, M.C (1997) Swiss-Model and Swiss-Pdb Viewer: an environment for comparative protein modeling Electrophoresis 18, 2714–2723.
49 Scha¨gger, H & von Jagow, G (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation
of proteins in the range from 1 to 100 kDa Anal Biochem 166, 368–379.
Trang 1050 Gurney, R.W (1953) Ionic Processes in Solution, pp 90–105.
McGraw-Hill, New York.
51 Karush, F (1962) Immunologic specificity and molecular
struc-ture Adv Immunol 2, 1–40.
52 Bjo¨rk, I., Brieditis, I., Raub-Segall, E., Pol, E., Ha˚kansson, K &
Abrahamson, M (1996) The importance of the second hairpin
loop of cystatin C for proteinase binding Characterization of the
interaction of Trp-106 variants of the inhibitor with cysteine
proteinases Biochemistry 35, 10720–10726.
53 Craven, C.J., Baxter, N.J., Murray, E.H., Hill, N.J., Martin, J.R., Ylinenja¨rvi, K., Bjo¨rk, I., Waltho, J.P & Murray, I.A (2000) Wild-type and Met-65 fi Leu variants of human cystatin A are functionally and structurally identical Biochemistry 39, 15783– 15790.
54 Guex, N., Diemand, A & Peitsch, M.C (1999) Protein modelling for all Trends Biochem Sci 24, 364–367.
55 Lakowicz, J.R (1983) Principles of Fluorescence Spectroscopy, pp 187–214 Plenum Press, New York.